|
|
|
| Study of the biodistribution and imaging of 99Tcm-MAG3-isoDGR-2C in tumor bearing mice |
| XIE Peng, HUANG Jian-min, LIU Xiao-mei, WEI Ling-ge |
| Department of Nuclear Medicine, the Third Affiliated Hospital of Hebei Medical University, Shijiazhuang 050051, China |
|
|
|
|
Abstract Objective: To study the feasibility of using labeled MAG3-isoDGR-2C with 99Tcm as a potential molecular imaging agent for ανβ3 targeting. Method: The MAG3-isoDGR-2C was labeled with 99Tcm using glucoheptonate transformation and complexation. S180 tumor bearing mice were divided into 5 groups with 5 mice each. At 30 min, 60 min, 120 min, 240 min and 360 min after the injection of 99Tcm-MAG3-isoDGR-2C, the mice were sacrificed by decapitating. The biodistribution in the organs, T/B and T/M was calculated. SPECT imaging was performed at different time points after injection in 5 tumor bearing mice, and the ratio of T/NT were calculated by using ROI. Results: The MAG3-isoDGR-2C was labeled with 99Tcm effectively and simply, and the radiation chemical purity could reach to 94.34% without purification. The biodistribution showed the tracer was cleared rapidly from blood and was mainly excreted through kidney. The radioactive uptake in heart, lung, spleen, stomach and bone was low, and the uptake in tumor could be visualized. The maximum ratios of T/B and T/NT were 1.75 and 10.50 respectively in the time of 4 hours after injection of the tracers. The SPECT images demonstrated the increased activity in the region of tumor with the maximum T/NT of 3.24±1.71. Conclusion: 99Tcm-MAG3-isoDGR-2C can be made easily and show certain targeting ability to the malignant process, which proves its potentiality to become a new molecular imaging agent.
|
|
Received: 10 November 2016
|
|
|
|
|
|
[1]Lee JW, Park JA, Lee YJ, et al. New glucocyclic RGD dimers for positron emission tomography imaging of tumor integrin receptors[J]. Cancer Biother Radiopharm, 2016, 31(6): 209-216.
[2]Kim YI, Yoon HJ, Paeng JC, et al. Prognostic value of 68Ga-NOTA-RGD PET/CT for predicting disease-free survival for patients with breast cancer undergoing neoadjuvant chemotherapy and surgery: a comparison study with dynamic contrast enhanced MRI[J]. Clin Nucl Med, 2016, 41(8): 614-620.
[3]王龙，唐军，刘增礼，等. 68Ga-DOTA-cRGD的制备及对荷肺腺癌裸鼠的显像研究[J]. 中华核医学与分子影像杂志，2016，36（2）：127-130.
[4]马庆杰，陈滨，高识，等. 99Tcm-3P4-RGD2与99Tcm-MIBI SPECT显像诊断乳腺癌的对比研究[J]. 中华核医学与分子影像杂志，2016，36（2）：184-185.
[5]Curnis F, Sacchi A, Gasparri A, et al. Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif[J]. Cancer Res, 2008, 68(17): 7073-7082.
[6]Folkman J. Role of angiogenesis in tumor growth and metastasis[J]. Semin Oncol, 2002, 29(6, Supplement 16): S15-18.
[7]Schirner M, Menrad A, Stephens A, et al. Molecular imaging of tumor angiogenesis[J]. Ann N Y Acad Sci, 2004, 1014(1): 67-75.
[8]Hwang R, Varner J. The role of integrins in tumor angiogenesis[J]. Hematol Oncol Clin North Am, 2004, 18(5): 991-1006.
[9]Jiao Y, Feng X, Zhan Y, et al. Matrix metalloproteinase-2 promotes αvβ3 integrin-mediated adhesion and migration of human melanoma cells by cleaving fibronectin[J]. PLoS One, 2012, 7(7): e41591.
[10]Vander Gucht A, Pomoni A, Jreige M, et al. 68Ga-NODAGA-RGDyK PET/CT imaging in esophageal cancer: first-in-human imaging[J]. Clin Nucl Med, 2016, 41(11): e491-e492.
[11]Jin ZH, Furukawa T, Degardin M, et al. ανβ3 integrin-targeted radionuclide therapy with 64Cu-cyclam-RAFT-c(-RGDfK-)4[J]. Mol Cancer Ther, 2016, 15(9): 2076-2085. |
|
|
|
